-+ 0.00%
-+ 0.00%
-+ 0.00%

ProQR Therapeutics Q3 2026 Net Loss Widens 13% Year on Year to €12.4 Million

PUBT·11/12/2026 12:22:17
ProQR Therapeutics Q3 2026 Net Loss Widens 13% Year on Year to €12.4 Million
  • ProQR Therapeutics’ third-quarter 2026 net loss widened 13% year over year to €12.4 million.
  • Research and development costs rose 29% year over year to €14.3 million.
  • Cash and cash equivalents totaled €103 million at September 30, 2026, supporting operations into mid-2028.
  • AX-0811’s first two Phase 1 cohorts are fully enrolled, with initial target engagement data expected in early January 2027.
  • The full AX-0810 Phase 1 dataset, including Cohort 3 and follow-up data, is expected in December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-125795), on November 12, 2026, and is solely responsible for the information contained therein.